share_log

NeuroSense Therapeutics | EFFECT: Others

NeuroSense Therapeutics | EFFECT: Others

NeuroSense Therapeutics | EFFECT:其他
美股SEC公告 ·  04/09 05:04

Moomoo AI 已提取核心信息

NeuroSense Therapeutics has received a Notice of Effectiveness from the United States Securities and Exchange Commission (SEC) on April 8, 2024. The notice, bearing the accession number 0001213900-24-030451, indicates that the company's submission, identified by the type POS AM and file number 333-260338, has been officially accepted by the SEC. This marks a significant regulatory milestone for NeuroSense Therapeutics, which is listed under the CIK number 0001875091.
NeuroSense Therapeutics has received a Notice of Effectiveness from the United States Securities and Exchange Commission (SEC) on April 8, 2024. The notice, bearing the accession number 0001213900-24-030451, indicates that the company's submission, identified by the type POS AM and file number 333-260338, has been officially accepted by the SEC. This marks a significant regulatory milestone for NeuroSense Therapeutics, which is listed under the CIK number 0001875091.
NeuroSense Therapeutics已于2024年4月8日收到美国证券交易委员会(SEC)的生效通知。该通知的注册号为0001213900-24-030451,表明该公司提交的文件已被美国证券交易委员会正式接受,其标识为POS AM类型,文件号为333-260338。这标志着NeuroSense Therapeutics的一个重要的监管里程碑,该公司以CIK的编号为0001875091上市。
NeuroSense Therapeutics已于2024年4月8日收到美国证券交易委员会(SEC)的生效通知。该通知的注册号为0001213900-24-030451,表明该公司提交的文件已被美国证券交易委员会正式接受,其标识为POS AM类型,文件号为333-260338。这标志着NeuroSense Therapeutics的一个重要的监管里程碑,该公司以CIK的编号为0001875091上市。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息